Loading…
← CockpitCompetitor Analysis › XENE Xenon Pharmaceuticals Inc.Open in the cockpit ↗

Xenon Pharmaceuticals Inc.XENECompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing ion-channel drugs; lead candidate azetukalner targets epilepsy and depression.

Momentum weak 21
Mkt cap
$3.71B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$52.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-188.9 pp
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$37.75
1D-2.7%
1W-10.3%
1M+4.1%
3M-36.8%
6M-31.0%
YTD-15.8%
1Y-7.0%
ATR %4.1%
Beta0.80
52w lowhigh48.0% off high

What Xenon Pharmaceuticals does

Clinical-stage biotech developing ion-channel drugs; lead candidate azetukalner targets epilepsy and depression.

Has no approved product, so revenue is limited to occasional milestone and collaboration payments from partners; trials are funded mainly by cash raised from selling shares. Value rests on late-stage results for azetukalner, which acts on potassium channels in nerve cells.

Products and services

  • Azetukalner (epilepsy/MDD)
  • Earlier ion-channel pipeline

Where it sits in the supply chain

  • Biopharma R&D
  • Ion-channel (Kv7) drug discovery
  • CNS clinical development

What could go right

  • Azetukalner approval/launch
  • Partnership milestone payments

What could go wrong

  • Late-stage trial failure risk
  • Competitive CNS/epilepsy market

Moat: none (IP / patents). Pre-commercial biotech; differentiation depends on azetukalner's late-stage trial results.

Headquarters: Vancouver, Canada · Founded: 1996 · Employees: 370

Named competitors

Xenon Pharmaceuticals at a glance

Size Xenon Pharmaceuticals (XENE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.71B, the 1387th largest of 3,085 United States companies the cockpit tracks. Shares closed at $37.75 on 18 Nov 2026.

Performance Over six months the shares fell 31.0%, against +5.7% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 19 in its peer set.

Growth Revenue fell 100.0% over the last twelve months (peer median +13.9%).

Capital Return on invested capital runs 188.9 points below its cost of capital (6.6% WACC).

Short interest Short interest is 7.6% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 107XENE 70
Six months, rebased to 100: Xenon Pharmaceuticals against the median of its 20 peers (local-currency closes).

Xenon Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$7.50M$0$0$9.43M
Revenue growth———-100%—
Gross profit-$2.32M$4.96M-$2.56M-$3.54Mn/a
EBITDA-$463M-$371M-$277M-$211M-$128M
Net income-$429M-$346M-$234M-$182M-$125M
Free cash flow-$352M-$280M-$184M-$151M-$101M
Capital expenditure$997,090$799,000$3.08M$5.62M$2.89M
Total debt$6.01M$7.94M$9.02M$10.9M$10.4M

Quarterly statements and history in the cockpit →

Xenon Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%1513TARSROVI600329SLSOGN6883363320WOCKPHARMASFZNACUTAAS1877ARQT128940DFTXAMLXXENE6-month return →1-month return →
Up and to the right = strong over both horizons. Xenon Pharmaceuticals is the large dot.

Xenon Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (XENE vs NBIX vs SUPN vs PRAX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Xenon Pharmaceuticals XENE$3.71B-31%-100%n/an/an/a
Neurocrine Biosciences NBIX$16.5B+5%+38%25%4.4×-1.5%
Supernus Pharmaceuticals SUPN$6.02B-41%+16%45%4.5×6.2%
Praxis Precision Medicines PRAX$8.53B-9%-100%n/an/an/a
Biohaven BHVN$1.95B+46%n/an/an/an/a
Axsome Therapeutics AXSM$7.05B-42%+54%-19%8.0×n/a
Jazz Pharmaceuticals Public JAZZ$15.9B+4%+13%25%4.0×-2.8%

How Xenon Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Xenon Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureXENEPeer medianRank in peer set
1-month return+4.1%-0.2%10th highest of 21
6-month return-31.0%+5.7%3rd lowest of 19
Distance from 52-week high-48.0%-24.8%4th lowest of 21
Revenue growth (TTM)-100.0%+13.9%lowest of 18
ROIC minus cost of capital-188.9 pp+5.9 pplowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%2.3×-7.0%+2.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%5.2×34.7%+159.5%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%4.2×1.2%+12.1%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%5.1×16.2%-5.8%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%1.8×-4.1%-1.0%
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%5.5×0.9%+45.1%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%3.2×6.4%+5.9%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%0.6×-4.9%+7.8%
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%9.3×58.0%+4.2%
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%27.6×57.4%+3.1%
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%2.8×n/an/a
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%20.4×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%8.4×n/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%6.6×49.2%+367.3%
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%3.3×4.7%+7.5%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%3.1×-2.1%+12.0%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a

Questions

Who are Xenon Pharmaceuticals's main competitors?
Named competitors: UCB (private or unlisted), SK Life Science (private or unlisted), Neurocrine Biosciences (NBIX), Supernus Pharmaceuticals (SUPN), Praxis Precision Medicines (PRAX), Biohaven (BHVN). The cockpit's measured peer set (industry) also includes Livzon Pharmaceutical (1513.HK), Tarsus Pharmaceuticals (TARS), Laboratorios Farmaceuticos Rovi (ROVI.MC), Tianjin Pharmaceutical Da Ren Tang (600329.SS), SELLAS Life Sciences (SLS), Organon & (OGN).
How has Xenon Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -31.0% against +5.7% for the median peer; over one year -7.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.